Ignite Creation Date:
2024-05-05 @ 11:21 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00000832
Status:
COMPLETED
Last Update Posted:
2021-11-04
First Post:
1999-11-02
Brief Title:
A Randomized Placebo-Controlled Double-Blinded Phase I Safety and Immunogenicity Trial of Recombinant Envelope Protein HIV-1 SF-2 rgp120 BIOCINE Combined With MF59 in HIV-1 Uninfected Adult Volunteers
Sponsor:
National Institute of Allergy and Infectious Diseases NIAID
Organization:
National Institute of Allergy and Infectious Diseases NIAID
Organization Data
Organization:
National Institute of Allergy and Infectious Diseases NIAID
Class:
NIH
Study ID:
AVEG 024
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
National Institute of Allergy and Infectious Diseases NIAID
Lead Sponsor Class:
NIH
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None